Evidence map›Paper›PMID 41096619›Full record

ArticleInternational journal of molecular sciences2025

Novel Type IIS-Based Library Assembly Technique for Developing Nanobodies Targeting IPNv VP2 Protein.

Camila Pino-Belmar, Johanna Himelreichs, Camila Deride, Tamara Matute, Isaac Nuñez, Severine Cazaux, Fernan Federici, Karen Moreno-Mendieta, Genaro Soto-Rauch, Joaquín Castro and 9 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Camila Pino-BelmarInstitute of Biochemistry and Microbiology, Faculty of Sciences, Universidad Austral de Chile, Valdivia 5110566, Chile.
Johanna HimelreichsInstitute of Medicine, Faculty of Medicine, Universidad Austral de Chile, Valdivia 5110566, Chile.
Camila DerideInstitute of Medicine, Faculty of Medicine, Universidad Austral de Chile, Valdivia 5110566, Chile.
Tamara MatuteAgencia Nacional de Investigación y Desarrollo-Millennium Science Initiative Program-Millennium Institute for Integrative Biology (iBio), Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.ORCID 0000-0002-0486-985X
Isaac NuñezAgencia Nacional de Investigación y Desarrollo-Millennium Science Initiative Program-Millennium Institute for Integrative Biology (iBio), Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.ORCID 0000-0002-4439-3745
Severine CazauxAgencia Nacional de Investigación y Desarrollo-Millennium Science Initiative Program-Millennium Institute for Integrative Biology (iBio), Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
Fernan FedericiAgencia Nacional de Investigación y Desarrollo-Millennium Science Initiative Program-Millennium Institute for Integrative Biology (iBio), Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
Karen Moreno-MendietaInstitute of Biochemistry and Microbiology, Faculty of Sciences, Universidad Austral de Chile, Valdivia 5110566, Chile.
Genaro Soto-RauchInstitute of Biochemistry and Microbiology, Faculty of Sciences, Universidad Austral de Chile, Valdivia 5110566, Chile.
Joaquín CastroBain & Company, Santiago 7550268, Chile.
Valentina FrenkelBain & Company, Santiago 7550268, Chile.
Joi-Hui HoBain & Company, Santiago 7550268, Chile.
David AscenciosBain & Company, Santiago 7550268, Chile.
Daniel Sanhueza TeneoInstitute of Immunology and Parasitology, Faculty of Medicine, Universidad Austral de Chile, Valdivia 5110566, Chile.ORCID 0009-0005-7159-4146
José MunizagaBiochemistry School, Faculty of Sciences, Universidad Austral de Chile, Valdivia 5110566, Chile.
Denise HaussmannDepartamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomás, Valdivia 5110566, Chile.
Alejandro Rojas-FernandezInstitute of Medicine, Faculty of Medicine, Universidad Austral de Chile, Valdivia 5110566, Chile.
Jaime Figueroa ValverdeInstitute of Biochemistry and Microbiology, Faculty of Sciences, Universidad Austral de Chile, Valdivia 5110566, Chile.
Guillermo Valenzuela-NietoFacultad de Ciencias para el Cuidado de la Salud, Universidad San Sebastián, Valdivia 5090000, Chile.

Funding

Bio&Medical Technology Development Program of the National Research Foundation (NRF) 680 funded by the Korean government (MSIT) RS-2025-1537319Fondap-National Agency for Research and Development (ANID) 1523A0007National Agency for Research and Development (ANID) 13220075National Agency for Research and Development (ANID) 2124176National Agency for Research and Development (ANID) 3220635National Agency for Research and Development (ANID) ICN17-022
6 · The paper itself

Abstract

The development of effective tools to combat viral diseases remains a major challenge for the aquaculture industry. Infectious pancreatic necrosis virus (IPNv) is one of the most devastating pathogens affecting salmonids, leading to high mortality rates and substantial economic losses worldwide. Here, we present a novel nanobody discovery pipeline based on a Type IIS restriction enzyme-driven library assembly method that enables the rapid generation of highly diverse nanobody repertoires. This streamlined approach not only shortens the time required for nanobody identification but also offers remarkable adaptability, allowing its application to virtually any protein target, including antigens from aquaculture pathogens and beyond. By integrating this strategy with density gradient-based enrichment and high-throughput screening, we successfully identified and validated a nanobody against the VP2 protein of IPNv, a key structural component essential for viral infectivity. These findings highlight the potential of this platform both as a versatile methodological advance in antibody engineering and as a practical foundation for developing innovative diagnostic and therapeutic tools. Ultimately, nanobodies generated through this pipeline could play a pivotal role in improving disease management and enhancing sustainability in aquaculture.

Indexed as

Antibodies, ViralInfectious pancreatic necrosis virusSingle-Domain AntibodiesAnimalsPeptide LibraryAntibodies, ViralPeptide LibrarySingle-Domain AntibodiesIPNvsingle domain antibodiesType IIS-based assembly methodsVP2

Identifiers

PMID41096619
PMCPMC12524851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.